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Advances in multimodality cancer treatments have increased the risk of long-term complications in early 
onset cancer survivors. For female cancer survivors these include diminished reproductive function, often 
resulting in a narrowed fertile window. The aim of this study was to evaluate the use of fertility treatments 
in cancer survivors (aged 0-39 years at diagnosis) compared to siblings. Data from Finnish registers on 
cancer, birth and prescribed medications were merged to identify 8,929 survivors and 9,495 siblings 
without previous deliveries. Fertility drug purchases from 1993 to 2012 at the age of 16-41 years were 
included. A Poisson regression model was used to estimate incidence rate ratios (IRR) for the use of fertility 
drugs, adjusting for age and calendar time at fertility drug purchase. Fertility treatments were more 
common in survivors compared to siblings, as 6.1% of survivors compared to 3.8% of siblings had bought 
fertility drugs (IRR 1.43, 95% confidence interval [CI] 1.25-1.65). A sub-classification of fertility treatments 
into ovulation inductions and assisted reproductive technology (ART), showed increased use of ART (IRR 
2.41, 95 % CI 1.97-2.96), whereas the use of ovulation induction was similar in survivors and siblings. 
Analyses by calendar time periods showed the use of ART to be significantly higher in the most recent 
decade, from 2003 onwards. We conclude that cancer survivors have an increased risk for subfertility, 
which is why fertility counselling is important. However, our results mirror a more active approach among 






















The population of early onset cancer survivors has been increasing over the past four decades, with 5-year 
survival rates reaching 80% in Finland as well as in Western Europe.
1, 2, 3 
As survival rates increase, so does 
the risk for chronic health conditions due to previous exposure to toxic anti-cancer treatments. Of these 
late effects, gonadal dysfunction and reduced fertility have been reported as major concerns among cancer 
survivors.
4 
A previous study 
5
 found that cancer treatments, especially abdominal radiation and 
chemotherapy with alkylating agents, may damage the ovaries, leading to diminished ovarian reserve, a 
narrowed fertile window and even premature ovarian insufficiency.  
 
Many studies have shown reduced parenthood and pregnancy rates in cancer survivors compared to 
siblings or the general population.
6-9
 There are, however, only a few studies focusing on infertility and even 
less on the use of fertility treatments among cancer survivors.
10,11
 One of them reported an increased risk 
for clinical infertility (defined as the inability to conceive after at least one year of unprotected intercourse 
during the fertile phase of the menstrual cycle) among survivors compared to siblings.
10
 In this study, 
survivors were as likely as their siblings to seek medical help for their infertility, but less likely to receive 
fertility treatments.
 10
 However, a previous study with the Finnish cohort 
11
 found that cancer survivors 
giving birth were more likely to undergo fertility treatments than their siblings were. Time elapsed from 
cancer treatment played a central role, with increasing use of fertility treatments over time. 
 
The aim of our study was to investigate whether female cancer survivors (diagnosed with cancer at the age 
of 0-39 years) receive more fertility treatments or fertility preservation than their siblings do, and if type of 
used fertility drug differed from that of siblings by the use of various Finnish register databases (FCR, CPR, 
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Materials and Methods 
In this retrospective, register-based study, we used data from four different national population-based 
registers: The Finnish Cancer Registry (FCR), the Central Population Register (CPR), the Medical Birth 
Register (MBR) and the Reimbursement Register for Prescribed Medicines (RPM). The registers were linked 
using the personal identity code (PIC) given to all Finnish citizens and residents. 
 
Registers 
The FCR is a population based national register on incident cancer cases since 1953. The coverage of the 
FCR is high, 96% for solid tumors and 86% for hematological malignancies. Of all cancers, 93% were 
morphologically verified.
12
 Data on cancer patients include: the PIC, details on cancer (site, histology and 
malignancy), treatment data (radiotherapy, chemotherapy, surgery and hormonal) and month as well as 
year of diagnosis. Clinical information is mainly provided by the treating physician and the histological data 
is notified by the pathology department. Childhood cancer diagnoses are categorized using the 




The CPR was founded in 1969 and computerized registration began in 1971. The register is national, 
covering all citizens and residents in Finland and includes data on residential history and death. Individuals 
born in 1955 or thereafter can be linked reliably to their parents, siblings and offspring. 
 
The MBR was established in 1987 and contains detailed information on all mothers giving birth as well as 
their children. Data is collected at the delivery hospital, using the maternity records of the mothers and 
includes information on all live births and stillbirths with a birth weight of more than 500 g or a pregnancy 
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The RPM has registered all purchased drugs since 1993. All refundable medications prescribed by public as 
well as by private health care providers are registered. Data include the purchase date of the prescription 
drug, the price of the medication and package size. All the drugs have been listed according to Anatomical 
Therapeutic Chemical codes (ATC codes) categories released by the World Health Organization. A study
15
 
comparing data from RPM and aggregated statistics of in vitro fertilization (IVF) in Finland, found the 





From the FCR, we identified 23,125 female cancer patients (hereafter referred to as survivors) diagnosed 
with a malignant neoplasm or benign brain tumor under the age of 40 years between January 1953 and 
December 2012 (Figure 1). Female siblings of survivors were identified from the CPR by maternal link using 
the PICs. We identified 20,542 female siblings of survivors. To eliminate possible influences of pregnancy 
history on the endpoint studied, we only included women without biological children before the time-point 
of fertility drug purchase. By linkage to the MBR, we could exclude women who were multiparous and by 
linking to the RPM, we could exclude women who had delivered before fertility drug purchase. This way, 
we identified 16,640 survivors and 18,184 siblings without deliveries prior to drug purchase between 1993 
and 2012.  
 
We excluded all women who were not in the age range of 16-41 years between 1993 and 2012 (when 
information on fertility drug purchase was available), and were left with 8,929 survivors and their 9,495 
siblings. Censoring events before drug purchase (Figure 1) included a pregnancy of more than 22 weeks or 
birth (a notification in the MBR), death, emigration, notification of aromatase inhibitor medication as a 
long-term anti-cancer treatment (registered in the RPM) or cancer diagnosis in a sibling. After these 
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The primary outcome analyzed was any fertility treatment, which was further sub-divided into ovulation 
induction (OI) and assisted reproductive technology (ART). ART refers to in vitro fertilization, intra-
cytoplasmic sperm injection and frozen embryo transfer. The most commonly used oral OI drugs are 
clomiphene citrate and aromatase inhibitors whereas gonadotropins are injectable drugs used for OI. These 
drugs are typically used for 3-6 cycles, commonly in combination with intrauterine insemination. During 
ART, a combination of gonadotropin releasing hormone (GnRH) analogues and gonadotropins is used. 
To sub-categorize fertility treatments in women as either OI or ART, we used information on fertility drug 
purchase during the following 21 days after an initial fertility drug purchase. 
A fertility treatment was classified as OI in the following cases: 
- Clomiphene citrate or aromatase inhibitor use, without use of any other fertility drug during the 
following 21 days 
- Gonadotropin use, without use of GnRH analogues 
Fertility treatments were classified as ART in the following cases: 
- A GnRH agonist or GnRH antagonist was the first drug used 
- Gonadotropin use in combination with  GnRH analogues 
In our data, time to event of four survivors was censored after being categorized into the any treatment 
group, but before categorization into the OI or the ART treatment group. Two siblings entered follow up 
after categorization into the any treatment group, but before categorization into the OI or ART treatment 
group (as their matched survivor received her cancer diagnosis after the sibling’s initial fertility drug 
purchase). Therefore, the numbers in the different treatment categories do not always add up to the 


















In this study, use of fertility treatments in cancer survivors and their siblings, was based on information on 
fertility drug purchase. We estimated incidence rates of fertility treatments (the number of events per 
10,000 person-years) by time period (1993-1997, 1998-2002, 2003-2007 and 2008-2012) and attained age 
(16-19, 20-24, 25-29, 30-34 and 35-41 years). Within each stratum of time period and attained age, we 
estimated the conditional probability of receiving a fertility treatment during a given age interval, given 
that the woman had not received fertility treatments before. We estimated incidence rate ratios (IRR) of 
fertility treatments in survivors compared to siblings, with 95% confidence intervals (CI) using Poisson 
regression models, adjusting for time period and attained age. A single, overall IRR, assuming no 
heterogeneity, was estimated. In addition, we fitted models that allowed heterogeneity in IRR by time 
period and age at fertility drug purchase and reported relative excess risk compared to a baseline IRR (age 
20-24 years, period 1993-1997). The statistical significance of the heterogeneity was tested using the 
likelihood ratio test and the level of statistical significance was set at p < 0.05. We plotted smoothed 




All analyses were conducted using R version 3.5.1. 
 
Ethics 
The National Institute for Health and Welfare (Dnr THL/1/5.05.00/2014) and the Social Insurance Institution 
(Dnr KELA/69/522/2014) approved this study protocol and granted a permit for the study. The permit 
process included an ethical evaluation. 
 
Results 
The descriptive and treatment characteristics of female cancer survivors are presented in Table 1. Most 
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adulthood at the age of 25-39 years (59.1%). Childhood cancer survivors (0-14 years when diagnosed) 
accounted for 15.7% of all survivors, and adolescents and young adults (15-24 years when diagnosed) for 
25.2%. The largest diagnostic group based on the ICCC3 classification consisted of carcinomas and other 
malignant epithelial neoplasms (50.6%). This group included breast cancers (15.7%), cancer of the thyroid 
gland (11.0%) and melanomas of the skin (7.9%) among others. The second largest diagnostic group 
consisted of lymphomas (13.0%), followed by tumors of the central nervous system (10.9%) and leukemia 
(7.7%). 
 
In our data (Table 1), most fertility treatments (65.3%) were given to adult cancer survivors and most often 
(44.7%) within three years of cancer diagnosis. Also most ART cycles were given to survivors who had been 
diagnosed with cancer within three years (60.1%). Of all cancer survivors, 49 (9.1%) were prescribed fertility 
drugs within 2 months after cancer diagnosis. Exploring the different cancer types, breast cancer survivors 
received the largest proportion of the fertility treatments (40.9%), the majority of ART cycles (55.2%) and a 
much smaller proportion of OI (12.7%).  
 
Of all cancer survivors, 541 (6.1%) were prescribed fertility drugs (Table 2). A majority, 64.3% of these 
fertility treatments, were ART. Of all siblings, 358 (3.8%) received fertility treatments, of which 39.4% were 
ART. As shown in Table 2, there was an overall increased use of fertility treatments in cancer survivors 
compared to siblings (IRR 1.43, 95% CI 1.25-1.65). A sub-classification of fertility treatments showed that 
the use of ART was significantly higher in cancer survivors (IRR 2.41, 95% CI 1.97-2.96) compared to siblings, 
whereas there was no increase in the use of OI (IRR 0.83, 95% CI 0.68-1.02). 
 
We observed statistically significant heterogeneity in IRR between age-groups and time periods in any 
fertility treatment and ART (Table 2). Compared to the first period, IRR between survivors and siblings was 
significantly larger in the most recent time periods. For example, IRR for use of ART was 3.39-fold (95% CI 
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was significantly smaller among 30-34 year old women (0.41-fold, 95% CI 0.17-0.97) as well as 35-41 year 
old women (0.35-fold, 95% CI 0.15-0.82) compared to those aged 20-24 years (Table 2). The IRR for OI was 
not significantly affected by time period or age. 
 
In Figure 2, the incidence rates of OI and ART are plotted against age at fertility drug purchase in different 
time periods. The incidence rates are given in table 3 (OI) and 4 (ART). In 1993-1997, the incidence rates for 
both OI and ART in survivors and siblings were quite similar. In OI, the same pattern could also be observed 
in 1998-2002. With regard to ART in 1998 to 2002, an increasing though non-significant gap in the incidence 
rates of survivors and siblings was visible. ART was more common among survivors than siblings in all age-
groups. The biggest difference in incidence rate during this time period was among women 25-29 years of 
age, as the incidence rate for survivors was 47/10,000 person years (Pyrs) compared to 26/10,000 Pyrs in 
siblings. During 2003 to 2007, the difference in incidence rates for ART became significant and was at its 
highest. For a survivor aged 25-29 years the incidence rate of receiving ART was 85/10,000 Pyrs whereas it 
was 11/10,000 Pyrs among siblings. At the age of 30-34 years the incidence rate was 150/10,000 Pyrs 
among survivors and 60/10,000 Pyrs among siblings. The incidence rates for OI were quite similar in 2003-
2007 and 2008-2012, siblings received more OI, especially in the higher age groups. During the most recent 
time period of 2008-2012, the difference in incidence rates decreased for ART, still remaining significantly 
higher in survivors compared to siblings in all age-groups.  
 
Discussion 
In our study, cancer survivors had a more than 1.4-fold use of overall fertility treatments compared to 
siblings. A sub-classification of overall fertility treatments into OI and ART revealed that this could be 
explained by ART, for which the use was more than 2.4-fold in survivors compared to siblings. Concerning 
OI, there was no difference between survivors and siblings and the risk was unaffected by age or time 
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A report from the Childhood Cancer Survivor Study
 10
 found a 48% increased risk for clinical infertility in 
cancer survivors, but on the contrary to our result cancer survivors were less likely than their siblings to be 
prescribed drugs for fertility treatment (RR 0.57, 95% CI 0.46-0.70). This study, however, evaluated fertility 
treatments between 1992 and 2004 and does not necessary reflect the situation in recent years. 
Furthermore, this study only included women younger than 21 years of age at cancer diagnosis whereas 
our study cohort includes women aged up to 40 years at cancer diagnosis. 
 
Our previous study found that Finnish female cancer survivors giving birth (aged 0-34 years at cancer 
diagnosis) had an almost two-fold risk for fertility treatments, during 2004-2013, compared to siblings.
11 
Survivors diagnosed as adults (at ages 25-34 years) had the highest odds for use of fertility treatments (OR 
2.31, 95% CI 1.01-5.32) whereas childhood cancer survivors (aged 0-14 years) had the lowest risk compared 
to siblings. Time elapsed from cancer treatment played a central role, increasing the need for fertility 
treatments compared to siblings, suggesting that cancer therapies might lead to diminished ovarian 
reserve. This finding is supported by another recent study
17
, in which the likelihood of a live birth was 
reduced after ART with autologous oocytes in cancer survivors. However, after ART with donor oocytes, the 
live birth rate was similar to that of siblings. 
 
To our knowledge, there are no published reports in the literature that uses a nationwide drug prescription 
register to explore use of fertility treatments in cancer survivors and their siblings. Studying fertility 
treatments in cancer survivors is of clinical importance, since they reflect possible gonadal damage caused 
by cancer treatments. They also mirror the attitudes of the treating physicians towards fertility treatments 
and fertility preservation in cancer survivors. In our study, 9.1% of all cancer survivors were prescribed 
fertility drugs within 2 months after cancer diagnosis, indicating that they were possibly fertility 
preservations. According to recent clinical guidelines, the possibility of infertility should be discussed with 
all cancer patients or their parents as early as possible after cancer diagnosis and when needed, fertility 
preservation should be considered.
18















 When it comes to recommended time between end of cancer treatment and pregnancy, 
there is no standard time interval. Instead, individual timing, taking into account cancer type, extent of 
disease and risk of relapse is recommended.
 20
 Also the age of the woman and her ovarian reserve should 
be taken into account.
20
 Regarding fertility treatments in female cancer survivors, one study on ART after 
breast cancer
21
 found no increased risk of relapse compared to survivors without fertility treatment. In this 
study, however, the majority of treatments consisted of oocyte donation and ovulation induction, which 
are procedures requiring no or low exposure to hormonal stimulation. In our study, 60% of all ART were 
given within three years of cancer diagnosis. 
 
When assessing the ovarian reserve in sub-fertile women, measurement of FSH and AMH serum levels as 
well as antral follicle count by ultra-sound, is used.
 22, 23 
Generally, OI is considered the first line treatment in 
ovulatory disorders and unexplained infertility, as it is less expensive, less invasive and easier to perform 
than ART. This was also the case for most siblings who received fertility treatments in our study. However, 
in survivors, the most common fertility treatment was ART, probably due to higher success rates than OI, 
especially when ovarian reserve is reduced. It is well known that cancer treatments, especially abdominal 
radiation and chemotherapy with alkylating agents, may damage the ovaries,
 
leading to a narrowed fertile 
time window in cancer survivors.
5, 11  
This probably explains the increased use of more advanced fertility 
treatments (ART) at the cost of easier, less invasive fertility treatments (OI) in cancer survivors. 
 
The main strength of our study is outcome ascertainment by use of a national drug prescription register to 
obtain outcome data, thus eliminating possible recall bias. Drugs classified as fertility drugs in our study are 
rarely used for other conditions. In our study, cancer survivors with a notification in the RPM of aromatase 
inhibitor use as an anti-cancer treatment (sometimes used in breast cancer) were censored from the study. 
Reliable population-based registers allowed identification of both cancer and sibling cohorts with no loss to 
follow-up, thus eliminating participation and selection bias. By comparing survivors with siblings, we were 














The main limitation of our study is that information on the indication for fertility treatment (male and 
female factors) is missing both in survivors and in siblings. In our data, women with fertility treatments 
using autologous oocytes are included. We could not obtain information on use of donated oocytes for ART 
in our cohort. In addition, information on whether the fertility drugs were used for fertility preservation or 
as fertility treatments was not available. Furthermore, it is possible that some women, who were entitled 
to reimbursement for fertility drug purchase, chose not to apply for it. This group of women is likely to be 
small,
 15
 as reimbursement is usually offered at the pharmacy and fertility drugs are often expensive. 
Limited duration of follow-up was available for women diagnosed with cancer in the most recent time 
period. In this study, results on pregnancy rates and live-birth rates after fertility treatments are not 
included. The results on successful fertility treatments resulting in a birth have been reported in a previous 
study of ours.
11
 Lastly, we would have liked to adjust for socioeconomic status, smoking and body mass 
index but this information was unavailable in the RPM. As siblings were used as the comparison group, we 
suspect the effect of socioeconomic status to be marginal.  
 
In conclusion, female cancer survivors receive more fertility treatments compared to their siblings, which 
can be explained by the increased use of ART. Time period of drug purchase played a central role and we 
observed a significantly increased use of ART in survivors compared to siblings from 2003 onwards. Our 
results mirror a more active approach among clinicians towards offering fertility treatments to cancer 
survivors in the most recent years.  
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      Descriptive characteristics and treatment characteristics of the female cancer survivor cohort 
Characteristics Survivors 
(N=8929) 
      N (%) 
Any fertility 
treatment (N=541) 







Year of diagnosis     
1963-1972 53 (0.59) 6 (1.11) 2 (1.06) 4 (1.15) 
1973-1992 3279 (36.72) 152 (28.10)
 1
 96 (50.79) 54 (15.52) 
1993-2012 5597 (62.68) 383 (70.79) 
1
 91 (48.15) 290 (83.33) 
Age at diagnosis     
0-14 1399 (15.67) 42 (7.76)
1
 28 (14.81) 13 (3.74) 
15-24 2251 (25.21) 146 (26.99)  65(34.39) 81 (23.28) 
25-39 5279 (59.12) 353 (65.25)
1
 96 (50.79) 254 (72.99) 
Time from diagnosis to 
treatment (years) 
    
0-2 N/A 242 (44.73)
 1
 31 (16.40) 209 (60.06) 
3-5 N/A 92 (17.01)
 
 37 (19.58) 55 (15.80) 
6-10 N/A 89 (16.45)
 1
 50 (26.46) 38 (10.92) 
11-41 N/A 118 (21.81)
 1
 71 (37.57) 46 (13.22) 
Cancer type     
Leukemia 688 (7.71) 22 (4.07)
 1
 12 (6.35) 9 (2.59) 
Lymphoma 1161 (13.00) 74 (13.68)
 1
 24 (12.70) 49 (14.08) 
Central Nervous System 970 (10.86) 30 (5.55)
 
 17 (8.99) 13 (3.74) 
Sympathetic Nervous System 77 (0.86) 1 (0.18) 1 (0.53) 0 (0.00) 
Retinoblastoma 31 (0.35) 2 (0.37) 1 (0.53) 1 (0.29) 
Renal Tumors 154 (1.72) 5 (0.92) 3 (1.59) 2 (0.57) 
Malignant bone Tumors 140 (1.57) 7 (1.29) 5 (2.65) 2 (0.57) 
Soft Tissue and other Sarcomas 338 (3.79) 13 (2.40) 7 (3.70) 6 (1.72) 
Germ cell, Gonadal and 
Trophoblastic neoplasms 
523 (5.86) 14 (2.59) 8 (4.23) 6 (1.72) 
Carcinomas and other malignant 
epithelial neoplasms 
4517 (50.59) 355 (65.62)
 1
 101 (53.44) 253 (72.70) 
Digestive system 532 (5.96) 23 (4.25) 16 (8.47) 7 (2.01) 
Breast 1402 (15.70) 221 (40.85) 24 (12.70) 196 (56.32) 
Melanoma of the skin 705 (7.90) 33 (6.47) 19 (10.05) 14 (4.02) 
Thyroid gland 982 (11.00) 53 (9.80) 27 (14.29) 26 (7.47) 
Others 896 (10.03) 25 (4.62) 15 (7.94) 10 (2.87) 
Others 93 (1.04) 8 (1.48) 5 (2.65) 3 (0.86) 
Missing 215 (2.41) 10 (1.85)
 1
 5 (2.65) 4 (1.15) 
Cancer treatment     
Chemotherapy 2903 (32.51) 212 (39.19)
 1
 49 (25.93)  162 (46.55) 
Radiotherapy 3204 (35.88) 235 (43.44)
 1
 66 (34.92) 168 (48.27) 
Surgery, only 3293 (36.88) 185 (34.20)
 
 81 (42.86) 104 (29.89) 
Other treatment 1121 (12.55) 58 (10.72)
 1 
 25 (13.23)  35 (10.06) 
          
OI, Ovulation induction; ART, assisted reproduction technology 
1
 time to event of 4 survivors were censored after being categorized into the any treatment 
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 Table 2 
 
Number of events and adjusted incidence rate ratios (IRRs) for different fertility treatments 
between 1993 and 2012 among female cancer survivors compared to their siblings 
 
 Any treatment OI ART 
Status    
Survivors N=8,929 N (%) 541 (6.06) 189 (2.12) 348 (3.90) 
Siblings N=9,495 N (%) 358 (3.77) 219 (2.31) 141 (1.48) 
    
Assuming no heterogeneity in IRR by age and time period (model M0) 
Overall IRR
1
  1.43 (1.25-1.65) 0.83 (0.68-1.02) 2.41 (1.97-2.96) 
    




(age 20-24, period 1993-1997 
1.32 (0.75-2.30) 0.60 (0.25-1.42) 2.28 (0.92-5.68) 
Relative excess risk compared to baseline IRR 
Age at drug 16-19 - - - 
purchase 20-24 1 1 1 
 25-29 0.66 (0.38-1.16) 1.69 (0.67-4.28) 0.62 (0.25-1.56) 
 30-34 0.86 (0.48-1.54) 1.64 (0.67-4.04) 0.41 (0.17-0.97) 
 35-41 0.59 (0.34-1.02) 1.14 (0.46-2.83) 0.35 (0.15-0.82) 
Test for heterogeneity p-value < 0.001
2
 p-value = 0.474
2
 p-value < 0.001
2
 
    
Period of drug 1993-1997 1 1 1 
purchase 1998-2002 1.24 (0.81-1.89) 0.91 (0.52-1.59) 1.73 (0.88-3.39) 
 2003-2007 2.31 (1.53-3.49) 1.01 (0.55-1.87) 3.39 (1.79-6.41) 
 2008-2012 1.73 (1.18-2.53) 0.89 (0.53-1.50) 2.65 (1.44-4.89) 
Test for heterogeneity p-value <0.001
3
 p-value = 0.959
3
 p-value < 0.001
3
 
IRR, incidence rate ratio; CI, confidence interval; OI, Ovulation induction; ART, Assisted 
reproductive technology 
Bold indicates statistically significant incidence rate ratio 
1
Adjusted for calendar period and age at possible fertility drug purchase 
Incidence rate of treatment was modelled using Poisson regression with following models for 
covariate effects: M0: age + period + status + age*period, M1:  age + period + status + age*period + 
age*status + period*status, M2:  age + period + status + age*period + age*status, M3:  age + period + 
status + age*period + period*status. 
2
p-value for comparing M1 vs M3 using likelihood ratio test 
3














Incidence and conditional probability of ovulation induction treatments in cancer survivors and siblings 

















Person years Incidence rate/10 
000 person years 
Conditional 
probability % 




1997 0 0 1233 1607 0 0 0 0 
 1998-
2002 0 0 1382 2160 0 0 0 0 
 2003-
2007 0 0 1411 2336 0 0 0 0 
 2008-
2012 0 0 1477 2792 0 0 0 0 
 Total 0 0 5503 8895     




1997 3 8 1570 1845 19 43 1 2.1 
 1998-
2002 2 4 2174 2650 9 15 0.5 0.8 
 2003-
2007 2 2 2274 3268 9 6 0.4 0.3 
 2008-
2012 1 4 2354 3624 4 11 0.2 0.6 
 Total 8 18 8372 11387     




1997 18 17 1618 2116 111 80 5.4 3.9 
 1998-
2002 9 13 1932 1907 47 68 2.3 3.4 
 2003-
2007 5 8 2463 2689 20 30 1 1.5 
 2008-
2012 10 14 2629 3307 38 42 1.9 2.1 
 Total 42 52 8642 10019     




1997 20 26 1873 2726 107 95 5.2 4.7 
 1998-
2002 11 18 1802 1978 61 91 3 4.4 
 2003-
2007 14 7 2064 1674 68 42 3.3 2.1 
 2008-
2012 19 25 2438 2304 78 109 3.8 5.3 
 Total 64 76 8177 8682     




1997 12 29 6914 7609 17 38 1.2 2.6 
 1998-
2002 12 12 4241 4620 28 26 2 1.8 
 2003-
2007 9 15 3542 2864 25 52 1.8 3.6 
 2008-
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  ART (N) Person years Incidence rate/10 
000 person years 
Conditional 
probability % 




1997 1 0 1233 1607 8 0 0.3 0 
 1998-
2002 1 0 1382 2160 7 0 0.3 0 
 2003-
2007 5 0 1411 2336 35 0 1.4 0 
 2008-
2012 6 0 1477 2792 41 0 1.6 0 
 Total 13 0 5503 8895     




1997 1 3 1570 1845 6 16 0.3 0.8 
 1998-
2002 7 0 2174 2650 32 0 1.6 0 
 2003-
2007 12 3 2274 3268 53 9 2.6 0.5 
 2008-
2012 11 2 2354 3624 47 6 2.3 0.3 
 Total 31 8 8372 11387     




1997 7 8 1618 2116 43 38 2.1 1.9 
 1998-
2002 9 5 1932 1907 47 26 2.3 1.3 
 2003-
2007 21 3 2463 2689 85 11 4.2 0.6 
 2008-
2012 25 8 2629 3307 95 24 4.6 1.2 
 Total 62 24 8642 10019     




1997 6 14 1873 2726 32 51 1.6 2.5 
 1998-
2002 12 11 1802 1978 67 56 3.3 2.7 
 2003-
2007 31 10 2064 1674 150 60 7.2 2.9 
 2008-
2012 36 7 2438 2304 148 30 7.1 1.5 
 Total 85 42 8177 8682     




1997 16 12 6914 7609 23 16 1.6 1.1 
 1998-
2002 20 14 4241 4620 47 30 3.2 2.1 
 2003-
2007 47 13 3542 2864 133 45 8.9 3.1 
 2008-














Incidence and conditional probability of ART treatments in cancer survivors and siblings according to age 
and time period of drug purchase 
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